TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8998248
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (HCTZ + AML) after 8 weeks of monotherapy
Study: 363217
Drug: Preoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative and postoperative metronidazole medication
Study: 363217
Drug: Preoperative mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative mechanical bowel preparation and oral neomycin
Study: 29600588
Drug: 6-month programmed
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month programmed sports therapy (PST)
Study: 23650950
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg HR, Thioctacid, three doses
Study: 9445301
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant human IL-5
Study: 7822813
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1ra) infusion (133 mg/h)
Study: 7822813
Drug: IL-1ra infusion
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IL-1ra infusion with endotoxin
Study: 7822813
Drug: Control study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control study day (no treatment)
Study: 2214478
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG (80 mg Tokyo strain) administered at one week intervals for 6 weeks, two week intervals for 12 weeks, and one month intervals for 20 months.
Study: 2214478
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no further treatment after TUR).
Study: 28685911
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention plus herbal medicine (two tablets: Tablet 1 with Cinnamomum verum, Glycyrrhiza glabra, Hypericum perforatum, Paeonia lactiflora; Tablet 2 with Tribulus terrestris)
Study: 28685911
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention plus herbal medicine
Study: 21802567
Drug: Daily dark
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL TOPICAL LOTION [La Roche Posay Laboratoire Dermatologique Pigmentclar Daily Dark Spot Correcting Moisturizer Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dark chocolate snack
Study: 19015329
Drug: Saquinavir/ritonavir (1,000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir/ritonavir (1,000/100 mg twice daily) alone for 14 days
Study: 19015329
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg once daily)
Study: 19015329
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of saquinavir/ritonavir and ketoconazole
Study: 19015329
Drug: Saquinavir/ritonavir (1,000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir/ritonavir (1,000/100 mg twice daily) with ketoconazole (200 mg once daily)
Study: 14722170
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine infusion of 10 micro g h(‐1) kg(‐1)
Study: 14722170
Drug: 3-hourly intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hourly intravenous morphine boluses of 30 micro g kg(‐1)
Study: 14722170
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride infusion of 5 micro g h(‐1) kg(‐1) at birth (term neonates)
Study: 14722170
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride infusion of 8.5 micro g h(‐1) kg(‐1) at 1 month
Study: 14722170
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride infusion of 13.5 micro g h(‐1) kg(‐1) at 3 months
Study: 14722170
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride infusion of 18 micro g h(‐1) kg(‐1) at 1 year
Study: 14722170
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride infusion of 16 micro g h(‐1) kg(‐1) for 1- to 3-yr-old children
Study: 11885871
Drug: Nifedipine 10-20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10-20 mg twice daily
Study: 8167511
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of alcohol in the form of beer, wine, or spirits with dinner
Study: 3280148
Drug: Controlled ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ventilation (IPPV) with halothane 0.5‐1%, N2O 66%, and pancuronium 0.05 mg.kg‐1 (n = 60)
Study: 26960416
Drug: Matured hop
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matured hop extract (MHE) containing 35 mg MHBA, ingested daily for 12 weeks.
Study: 26960416
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage without MHE, ingested daily for 12 weeks.
Study: 18984759
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (25 patients)
Study: 11170151
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto extract (320 mg o.d.)
Study: 9670433
Drug: HBO2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 therapy at 2.5 atm abs pressure for 90 min daily for a total of five treatments, starting 1 h after the operation.
Study: 31051059
Drug: HBO2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 therapy
Study: 9670433
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HBO2 therapy)
Study: 2980760
Drug: Medication M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication M (Monobeltin) - 1,050 mg ASA with enteric coat
Study: 2980760
Drug: Medication C
Normalized name: POUCH,MEDICATION CRUSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication C (Colfarit) - 1,000 mg microencapsulated ASA
Study: 29985380
Drug: Para-articular oxygen/ozone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Para-articular oxygen/ozone therapy at a permanent ozone concentration of 8 gr/l (injection area 15-20 sq.cm)
Study: 29985380
Drug: Generic drug-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic drug-based treatment alone
Study: 29985380
Drug: Para-articular oxygen/ozone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Para-articular oxygen/ozone therapy
Study: 29985380
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with oxygen/ozone therapy
Study: 27155232
Drug: UVB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB treatment (4.3-8.7 J/cm²)
Study: 27155232
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral drops and Woods lamp)
Study: 23086704
Drug: Mild protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild protocol (FSH 150 IU/day from day 4 followed by GnRH-antagonist from day 8; n=205)
Study: 20583915
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with autogenous periosteal membranes and autogenous bone chips (aCPRT)
Study: 18025536
Drug: ARC1779 (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARC1779 (0.05 to 1.0 mg/kg)
Study: 16128862
Drug: rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 40 mg day(-1) for 12 weeks
Study: 11292279
Drug: Individuals with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals with one or two long (l) 5HTTLPR alleles
Study: 11292279
Drug: Individuals with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals with one or two long (l) 5HTTLPR alleles or higher CSF 5HIAA levels
Study: 8719005
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg gemeprost vaginal pessary administered at 6h intervals
Study: 25970116
Drug: Intravenous PTX
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PTX 5 mg/kg/hr for 6 hours on 6 successive days
Study: 23234647
Drug: Mavrilimumab 10
Normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab 10 mg
Study: 23234647
Drug: Mavrilimumab 50
Normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab 50 mg
Study: 19829036
Drug: IV midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV midazolam (1 ml)
Study: 15561813
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 U weekly (QW)
Study: 8221741
Drug: Captopril pretreatment
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril pretreatment (6.25 mg orally 15 min before thrombolysis) in Group A
Study: 8221741
Drug: Captopril late
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril late treatment (administered about 3 days after thrombolysis) in Group B
Study: 8221741
Drug: Captopril late
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril late treatment in Group B
Study: 30656782
Drug: Endodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment
Study: 30656782
Drug: Prophylaxis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis and topical fluoride (control)
Study: 18756983
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (clopidogrel 75 mg plus aspirin 100 mg)
Study: 18756983
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (low molecular weight heparin for 7 days plus long-term warfarin)
Study: 16179787
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rabeprazole for 2 days and 1 hour before the test
Study: 12540640
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy with calcium disodium EDTA for 3 months followed by repeated therapy weekly for 24 months (32 patients with high-normal body lead burdens).
Study: 12540640
Drug: Placebo infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions for 5 weeks every 6 months (32 control patients).
Study: 10100068
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with low renin levels (< 10 mU/l; n = 118)
Study: 10100068
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving diuretics (n = 39)
Study: 10100068
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving beta-blockers (n = 54)
Study: 10100068
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving angiotensin-converting enzyme inhibitors (n = 9)
Study: 10100068
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving Ca(2+)-antagonists (n = 19)
Study: 29920980
Drug: Bapineuzumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab (5 mg, 10 mg, 20 mg, 40 mg, 80 mg)
Study: 25166750
Drug: 3000 IU
Normalized name: Cholecalciferol 3000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 IU of oral cholecalciferol daily for 4 months
Study: 17599630
Drug: alpha-galactosylceramide (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-galactosylceramide (any dose)
Study: 14701781
Drug: Methadone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (7.5 mg orally every 12 hours and 5 mg every 4 hours as needed)
Study: 14701781
Drug: Morphine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (15 mg sustained release every 12 hours and 5 mg every 4 hours as needed)
Study: 3528988
Drug: Both Methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Methadone and Morphine
Study: 10396343
Drug: Melarsoprol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melarsoprol treatment
Study: 7978143
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol infusion while breathing 100% oxygen
Study: 27824253
Drug: 3.5 ml
Normalized name: ethanol 3.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 ml of radiolabeled (1 mCi 99mTc-DTPA) universal placebo, hydroxyethyl cellulose gel
Study: 27824253
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of radiolabeled (1 mCi 99mTc-DTPA) universal placebo, hydroxyethyl cellulose gel
Study: 25926088
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (2,500 U)
Study: 25926088
Drug: High-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose heparin (5,000 U)
Study: 19218138
Drug: Phosphocreatine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphocreatine treatment (8 weeks)
Study: 2666363
Drug: Adjuvant CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CMF chemotherapy
Study: 3904436
Drug: Isoxicam at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxicam at a dosage greater than 200 mg per day
Study: 3904436
Drug: Isoxicam at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxicam at 200 mg per day
Study: 3904436
Drug: Buffered aspirin
Normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered aspirin at 3,600 to 4,800 mg per day
Study: 3904436
Drug: Indomethacin at
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin at 150 mg per day
Study: 31166081
Drug: Fasudil 60
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 60 mg
Study: 31166081
Drug: Fasudil 30
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 30 mg
Study: 30307816
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution containing betaine, zinc and polyhexamethylene biguanide (polihexanide)
Study: 30307816
Drug: 3% saline
Normalized name: dextrose 2.5%-0.3% saline (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% saline solution containing 0.2% sodium hypochlorite
Study: 30307816
Drug: Irrigation solution
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation solution containing sea salt 1.2% and NaOCl 0.4%
Study: 24382109
Drug: Culturally Adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally Adapted Cognitive Behaviour Therapy for Psychosis (CaCBTp)
Study: 24279026
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group D, control)
Study: 21262590
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of combined oral estroprogestins (CON)
Study: 21262590
Drug: Cyclic administration
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic administration of combined oral estroprogestins (CYC)
Study: 12698853
Drug: Doxocycline (DC)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxocycline (DC) 200 mg/day
Study: 12698853
Drug: Erythromycin (EM)
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin (EM) 2 g/day
Study: 12698853
Drug: Ciprofloxacin (CF)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CF) 1 g/day
Study: 12698853
Drug: Co-trimoxazole (CT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (CT) 1920 mg/day
Study: 8365932
Drug: Progressively higher
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressively higher total doses of hepatic irradiation
Study: 3521717
Drug: Acyclovir tablets
Normalized name: Acyclovir Tablets
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir tablets (400 mg) administered five times daily
Study: 3521717
Drug: Acyclovir ophthalmic
Normalized name: acyclovir Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir ophthalmic ointment administered five times daily
Study: 18481719
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point sticking combined with Tongshiji treatment
Study: 18481719
Drug: Simple Tongshiji
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Tongshiji treatment (control group)
Study: 1587377
Drug: Immunotherapy utilizing
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy utilizing the husband's lymphocytes
Study: 1587377
Drug: Immunosuppressant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressant and anticoagulant therapy
Study: 1587377
Drug: Immunotherapy indicated
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy indicated but not received
Study: 2876719
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion (0.4 to 0.5 micrograms kg‐1 min‐1)
Study: 2876719
Drug: Pethidine infusion
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine infusion
Study: 24139824
Drug: CaD (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaD (700 mg calcium + 200 IU vitamin D)
Study: 24139824
Drug: CaDEA (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaDEA (700 mg calcium + 200 IU vitamin D + 12 IU vitamin E + 2,000 IU vitamin A)
Study: 24139824
Drug: Ca (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca (700 mg calcium)
Study: 19616498
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV), three doses
Study: 19616498
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV), two doses
Study: 19616498
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV), one dose
Study: 9497213
Drug: Endoscopic variceal
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic variceal ligation therapy (EVL)
Study: 9497213
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection variceal sclerotherapy (EVS)
Study: 9497213
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EVL plus low-dose EVS
Study: 7961545
Drug: Venlafaxine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75 to 375 mg/day)
Study: 7961545
Drug: Venlafaxine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (200 mg/day)
Study: 7961545
Drug: Venlafaxine (201-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (201-300 mg/day)
Study: 7961545
Drug: Venlafaxine (>
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (> 300 mg/day)
Study: 31755939
Drug: Thrombin‐activatable fibrinolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin‐activatable fibrinolysis inhibitor activation peptide antigen
Study: 21793899
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of carcinine
Study: 21793899
Drug: Parabulbar, subconjunctival,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parabulbar, subconjunctival, and intravitreal injection of carcinine
Study: 20642550
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg once daily)